Literature DB >> 9561492

Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.

M Tod1, J M Rocchisani.   

Abstract

Optimization of the sampling schedule can be used in pharmacokinetic (PK) experiments to increase the accuracy and the precision of parameter estimation or to reduce the number of samples required. Several optimization criteria that formally incorporate prior parameter uncertainty have been proposed earlier. These criteria consist in finding the sampling schedule that maximizes the expectation (over a given parameter distribution) of det F (ED-optimality) or Log(det F) (API-optimality), or minimizes the expectation of 1/det F (EID-optimality), where F is the Fisher information matrix. The precision and the accuracy of parameter estimation after having fitted a PK model to a small number of optimal data points (determined according to D, ED, EID, and API criteria) or to a naive sampling schedule were compared in a Monte Carlo simulation study. A one-compartment model with first-order absorption rate (3 parameters) and a two-compartment model with zero-order infusion rate (4 parameters) were considered. Data were simulated for 300 subjects with both structural models, combined with several residual error models (homoscedastic, heteroscedastic with constant or variable coefficient of variation). Interindividual variabilities in PK parameters ranged from 25-66%. ED-, EID-, and API-optimal sampling times were calculated using the software OSP-Fit. Three or five samples were allowed for parameter estimation by extended least-squares. Performances of each design criterion were evaluated in terms of mean prediction error, root mean squared error, and number of acceptable estimates (i.e., with a SE less than 30%). Compared to the D-optimal design, the EID and API designs reduced the bias and the imprecision of the estimation of the parameters having a large interindividual variability. Moreover, the API design resulted in some cases in a higher number of acceptable estimates.

Mesh:

Year:  1997        PMID: 9561492     DOI: 10.1023/a:1025701327672

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  12 in total

1.  Optimal sampling theory and population modelling: application to determination of the influence of the microgravity environment on drug distribution and elimination.

Authors:  G L Drusano
Journal:  J Clin Pharmacol       Date:  1991-10       Impact factor: 3.126

2.  Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments.

Authors:  D Z D'Argenio
Journal:  Math Biosci       Date:  1990-04       Impact factor: 2.144

3.  Optimal experiment design for nonlinear models subject to large prior uncertainties.

Authors:  E Walter; L Pronzato
Journal:  Am J Physiol       Date:  1987-09

4.  Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection.

Authors:  T M Ludden; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1994-10

5.  Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model.

Authors:  Y Merlé; F Mentré
Journal:  J Pharmacokinet Biopharm       Date:  1995-02

6.  Application of optimal sampling theory to the determination of metacycline pharmacokinetic parameters: effect of model misspecification.

Authors:  M Tod; C Padoin; K Louchahi; B Moreau-Tod; O Petitjean; G Perret
Journal:  J Pharmacokinet Biopharm       Date:  1994-04

7.  Designing an optimal experiment for Bayesian estimation: application to the kinetics of iodine thyroid uptake.

Authors:  Y Merlé; F Mentré; A Mallet; A H Aurengo
Journal:  Stat Med       Date:  1994-01-30       Impact factor: 2.373

8.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

9.  Optimal sampling times for pharmacokinetic experiments.

Authors:  D Z D'Argenio
Journal:  J Pharmacokinet Biopharm       Date:  1981-12

10.  Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria.

Authors:  M Tod; J M Rocchisani
Journal:  Comput Methods Programs Biomed       Date:  1996-06       Impact factor: 5.428

View more
  13 in total

1.  Robust optimal design for the estimation of hyperparameters in population pharmacokinetics.

Authors:  M Tod; F Mentré; Y Merlé; A Mallet
Journal:  J Pharmacokinet Biopharm       Date:  1998-12

2.  Optimization of individual and population designs using Splus.

Authors:  Sylvie Retout; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

3.  Robust population pharmacokinetic experiment design.

Authors:  Michael G Dodds; Andrew C Hooker; Paolo Vicini
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-02       Impact factor: 2.745

4.  Simultaneous versus sequential optimal design for pharmacokinetic-pharmacodynamic models with FO and FOCE considerations.

Authors:  J M McGree; J A Eccleston; S B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-02-18       Impact factor: 2.745

5.  D-optimal designs for parameter estimation for indirect pharmacodynamic response models.

Authors:  Leonid A Khinkis; Wojciech Krzyzanski; William J Jusko; William R Greco
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-11       Impact factor: 2.745

6.  Optimal design in population kinetic experiments by set-valued methods.

Authors:  Peter Gennemark; Alexander Danis; Joakim Nyberg; Andrew C Hooker; Warwick Tucker
Journal:  AAPS J       Date:  2011-07-15       Impact factor: 4.009

7.  Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology.

Authors:  Giulia Lestini; Cyrielle Dumont; France Mentré
Journal:  Pharm Res       Date:  2015-06-30       Impact factor: 4.200

8.  Some considerations on the design of population pharmacokinetic studies.

Authors:  Stephen Duffull; Tim Waterhouse; John Eccleston
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

9.  Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Experiments in Mice.

Authors:  Giulia Lestini; France Mentré; Paolo Magni
Journal:  AAPS J       Date:  2016-06-15       Impact factor: 4.009

10.  Optimal sampling schedule design for populations of patients.

Authors:  Vincent H Tam; Sandra L Preston; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.